From bench to clinic with apoptosis-based therapeutic agents

By D. Nicholson. Nature, 2000

717 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/df6cc0038e589c65ae1beb890c0de23063054098

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

Citations in the corpus

Caspase-independent cell death (2005, background): “So, although polycaspase inhibitors such as Z-VAD-fmk are effective against most caspases, whether such inhibitors can effectively neutralize all caspases that are activated during apoptosis has been the subject of considerable debat”
Apoptosis: A Review of Programmed Cell Death (2007, background): “As our understanding of the field evolves, the identification and exploitation of new targets remains a considerable focus of attention (Nicholson, 2000).”
Pathophysiology of ischemic acute kidney injury (2011, background): “Inhibition of caspase activity has been shown to be protective against injury in vitro and in AKI in vivo”
Promoting apoptosis as a strategy for cancer drug discovery (2005, background): “Therefore, drugs designed to restore programmed cell death might be effective against many cancer”
Pathophysiology and pharmacologic treatment of acute spinal cord injury. (2004, background): “Other strategies to prevent apoptosis involve pharmacologic caspase inhibitors and the application of genes for proteins that inhibit the pathways leading to caspase activation, such as Bcl-2 [47–49].”
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo (2002, background): “Despite aggressive therapies, resistance of many tumors to current treatment protocols due to apoptosis defects remains a major problem in cancer therap”
The Bcl-2 family: roles in cell survival and oncogenesis (2003, background): “Promising attempts to minimize cell death are focused on caspase inhibitors (Nicholson, 2000).”
Inflammatory Resolution: new opportunities for drug discovery (2004, background): “It is clear that apoptosis has a fundamental role in almost all biological processes and there is increasing evidence to indicate that dysregulated apoptosis is likely to be an important factor in the pathogenesis and progression of a number of disease”
NOBEL LECTURE: Worms, Life and Death (2003, background): “, see [102–105]), and here I will note only that either too much or too little cell death can cause disease.”
Validating survivin as a cancer therapeutic target (2003, result): “Apoptosis-based cancer therapy is still in its infancy, but its underlying premise has passed proof of principle, and early clinical trials have provided limited but encouraging initial result”
Apoptosis-based therapies (2002, background): “The relative merits of broad-spectrum versus selective caspase inhibitors, and the issues that surround reversible versus irreversible drugs, have been debated within the context of acute versus chronic indications and other pertinent issue”